[The Editors' Verdict]The Cost of the Easy Choice: Cutting Drug Prices
Are We Prepared to Pay the Long-Term Opportunity Cost?
We Must Carefully Weigh the Fallout of a Weakened Industry
The government's drug price reduction policy is akin to a game in which industrial opportunity costs are paid in exchange for short-term and visible results. In the face of the challenging issue of alleviating the National Health Insurance (NHI) fund burden, the government seems to be choosing the most straightforward route. The causes behind the deterioration of the NHI finances are complex. They include the increased demand for medical services due to an aging population, the expansion of chronic disease management targets, the broader coverage of high-cost medical technologies and new drugs, and inefficiencies in the healthcare delivery system.
Although drug prices are only a small part of this equation, the policy focus repeatedly falls on drug prices, likely because the government finds them relatively easy to control. As a result, lowering drug prices becomes an attractive policy tool. It can deliver a fiscal saving of several hundred billion won in a short period and makes it easy to send a political message that the "public's burden has been reduced."
The real issue is where these costs emerge. The moment drug prices are lowered, a portion of the fiscal burden is shifted onto pharmaceutical companies, that is, the industry itself. While the government may claim that its intention is to address the oversupply of generic drugs and an inefficient price structure, there are doubts as to whether this logic is sufficient to justify a comprehensive price cut. The biggest problem with drug price reductions is that their losses do not become immediately apparent.
Problems such as the weakening of industrial capability, the reduction of research and development (R&D), and the instability in the supply of essential medicines appear gradually and with a time lag. In the policy-making process, short-term results tend to be overestimated, while medium- and long-term costs are underestimated. The drug price reduction policy is a classic example of this.
The pharmaceutical industry is a high-risk, long-term investment sector. Developing a single new drug requires more than 10 years and massive capital. In this structure, the reason companies are willing to take risks is the reward they receive if successful. If drug prices are lowered across the board, this reward structure is weakened. The first area that companies cut is not promotional expenses, but R&D expenses. As a result, both the quantity and quality of new drugs developed domestically are likely to decline, and these side effects will ultimately circle back to the NHI finances.
If the basic and potential strength of our pharmaceutical industry weakens, reliance on high-priced new drugs from foreign pharmaceutical companies will increase. In other words, the fiscal savings achieved by lowering drug prices in the short term may end up being offset by higher drug costs in the medium to long term. This is a paradox in which a policy aimed at reducing fiscal expenditure may actually increase costs. The issue of essential medicines is similar. For products with low profitability, companies have less incentive to continue production. If production is halted or supply is reduced, the government will have to intervene again through subsidies, incentives, or emergency imports, resulting in yet another form of fiscal expenditure.
In this sense, drug price reduction appears to be more of a political choice than a fiscal policy. The rational approach is to move away from this binary thinking. If a drug price cut is truly urgent and unavoidable, it is necessary to spend considerable time deliberating on methodologies such as differentiated compensation based on value, rather than indiscriminate reductions. For instance, a value-based system that assigns sufficient value to highly innovative and therapeutically valuable drugs, thereby creating room for overall readjustment, should be carefully considered.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
One of the key lessons learned from weathering the COVID-19 crisis is the efficacy of a stable pharmaceutical supply base, and its foundation is the industry itself. This is not an issue to be approached solely through short-term profit and loss calculations, and even from an economic standpoint, it cannot be confidently asserted that the current approach is correct if implemented properly.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.